A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures

Seizure : the Journal of the British Epilepsy Association
R G BeranF Vajda

Abstract

The efficacy and tolerability of vigabatrin as add-on therapy was assessed in patients with uncontrolled partial seizures. Ninety-seven patients entered this seven-centre, double-blind, placebo-crossover study. Vigabatrin (2 g or 3 g) or placebo was administered daily. Vigabatrin was well-tolerated and did not cause clinically significant adverse drug effects when added to established anticonvulsant therapy. No significant differences were observed between dose groups for the overall incidence of adverse events, although drowsiness and visual disturbances (diplopia, ataxia, visual abnormalities) showed a dose-related increase with vigabatrin treatment. The results of this study indicate that vigabatrin, given in a daily dose of either 2 g or 3 g is significantly more effective than placebo in reducing seizure frequency among patients with partial seizures.

References

Sep 1, 1992·Acta Neurologica Scandinavica·A TartaraE Perucca
Jan 1, 1990·Quality Assurance in Health Care : the Official Journal of the International Society for Quality Assurance in Health Care·G K Daikos
Jan 1, 1989·British Journal of Clinical Pharmacology·J P Mumford, M Dam
Jan 1, 1989·British Journal of Clinical Pharmacology·B S Meldrum
Sep 1, 1987·Archives of Neurology·C A TassinariF Salvi
Aug 1, 1993·Journal of Neurology, Neurosurgery, and Psychiatry·H A RingE H Reynolds

❮ Previous
Next ❯

Citations

Aug 14, 2012·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Haiyan HanZheng Xue
Aug 25, 2001·Epilepsia·D M Treiman
Jul 1, 1999·Epilepsia·J A CramerR H Mattson
Oct 24, 2009·Neuropsychiatric Disease and Treatment·Elizabeth J WaterhouseSoundarya N Gowda
Nov 14, 2014·CNS Drugs·J van GaalenB P C van de Warrenburg
Dec 12, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S Arroyo, G Kramer
Apr 5, 2016·International Journal of Clinical Practice·R G BeranM E Beran
Feb 27, 2013·The Cochrane Database of Systematic Reviews·Karla HemmingAnthony G Marson
Jul 31, 2020·The Cochrane Database of Systematic Reviews·Rebecca BresnahanAnthony G Marson
Jan 12, 2000·The Annals of Pharmacotherapy·B E GidalJ T Gilman
Jun 19, 2012·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Renzo GuerriniAnna Rosati

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.